Clinical trials: Prostate Cancer Stage
Prostatic Neoplasms
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
This is a phase 3 study to compare the clinical benefit of abiraterone acetate plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed one or two…
- Trial name
- NCT00638690
- Testing
- Abiraterone acetate, Prednisone/prednisolone
- Where
- 127 sites in United States, Australia and 10 more
- Volunteers
- 1,195 people
- Sponsor
- Cougar Biotechnology, Inc.
Prostate Cancer
Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
Provenge is an investigational product designed to activate a man's own antigen presenting cells, a type of immune cell, so that they can detect prostate cancer cells and initiate an immune response against them.
- Trial name
- NCT00065442
- Testing
- Sipuleucel-T
- Where
- 71 sites in United States, Canada
- Volunteers
- 512 people
- Sponsor
- Dendreon
Metastatic Castration-resistant Prostate Cancer
Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer
This research study is evaluating a drug called enzalutamide in metastatic castration resistant prostate cancer. Enzalutamide is already FDA approved for metastatic castration resistant prostate cancer after treatment with…
- Trial name
- NCT01942837
- Testing
- Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 67 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer, Prostate Adenocarcinoma
Trial of NanoPac Focal Therapy for Prostate Cancer
This study evaluates the use of NanoPac injected directly into the prostate lesion in men with prostate cancer.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Adenocarcinoma, Prostatic Neoplasm
- Trial name
- NCT04221828
- Testing
- NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- NanOlogy, LLC
Prostate Cancer
A Long Term Safety Study of Degarelix in Patients With Prostate Cancer
Patients that completed any of the trials; CS27 (NCT00738673), CS28 (NCT00831233), CS30 (NCT00833248) or CS31 (NCT00884273) will be given the opportunity to receive monthly doses of degarelix until the drug is launched in their…
- Trial name
- NCT00967018
- Testing
- Degarelix
- Where
- 62 sites in Belgium, France and 5 more
- Volunteers
- 77 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
The purpose of this study is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for participants with mHSPC.
- Trial name
- TITAN (NCT02489318)
- Testing
- Apalutamide, Androgen Deprivation Therapy (ADT)
- Where
- 220 sites in United States, Argentina and 20 more
- Volunteers
- 1,052 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Prostate Cancer
Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status
Radium-223 is indicated for the treatment of patients with mCRPC with symptomatic bone metastases and no known visceral metastatic disease.
- Trial name
- EXCAAPE (NCT03002220)
- Testing
- radium-223
- Where
- 6 sites in Spain
- Volunteers
- 52 people
- Sponsor
- MedSIR
Metastatic Prostate Cancer, Non-metastatic Prostate Cancer
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
This research study is trying to determine the safety and efficacy of the combination of two oral drugs, abemaciclib and darolutamide, with androgen deprivation therapy (ADT) in the treatment of metastatic, non-metastatic, and…
- Conditions
- Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer
- Trial name
- NCT05617885
- Testing
- Darolutamide, Abemaciclib, GNRH-A Leuprolide Acetate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Praful Ravi, MB BCHir, MRCP
Prostatic Neoplasms, Prostate Cancer
Study of Diagnostic Performance of [18F]CTT1057 in BCR
The current study aimed at evaluating the diagnostic performance of [18F]CTT1057 as a PET imaging agent for detection and localization of Prostate specific membrane antigen (PSMA) positivity in patients diagnosed of biochemical…
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Recurrence
- Trial name
- GuidePath (NCT04838613)
- Testing
- [18F]CTT1057, [68Ga]Ga-PSMA-11
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 190 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer, Adenocarcinoma of the Prostate
Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy
The main purpose of this trial is to collect information and to evaluate the effects, good or bad, the combination of docetaxel and bevacizumab has on patients with high risk prostate cancer that are undergoing radical…
- Trial name
- NCT00321646
- Testing
- Bevacizumab, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Mary-Ellen Taplin, MD
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This phase II trial studies how well ipilimumab works when given together with androgen suppression therapy in treating patients with hormone-resistant prostate cancer that has spread to other parts of the body.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01498978
- Testing
- ipilimumab, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- OHSU Knight Cancer Institute
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance
This randomized phase II trial studies how well PROSTVAC (prostate-specific antigen [PSA]-TRICOM) works in preventing disease progression in patients with prostate cancer undergoing active surveillance.
- Trial name
- NCT02326805
- Testing
- Laboratory Biomarker Analysis, Rilimogene Galvacirepvec
- Where
- 7 sites in United States
- Volunteers
- 154 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Sulforaphane in Treating Patients With Recurrent Prostate Cancer
This phase II trial studies how well sulforaphane works in treating patients with recurrent prostate cancer. Sulforaphane may prevent or slow the growth of certain cancers.
- Trial name
- NCT01228084
- Testing
- Sulforaphane, Laboratory biomarker analysis, Pharmacological study
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- OHSU Knight Cancer Institute
Head and Neck Neoplasm, Prostatic Neoplasm
Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms
Phase 1 safety, pharmacokinetics, and pharmacodynamics trial of the focal adhesion kinase (FAK) inhibitor PF-00562271 in patients with positive Positron Emission Tomography [PET] scans due to advanced non-hematologic…
- Conditions
- Head and Neck Neoplasm, Prostatic Neoplasm, Pancreatic Neoplasm
- Trial name
- NCT00666926
- Testing
- PF00562271
- Where
- 4 sites in United States, Australia and 1 more
- Volunteers
- 99 people
- Sponsor
- Verastem, Inc.
Adenocarcinoma of the Prostate
Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer
Open-label, dose rising, Phase IIa trial of intratumorally-injected NanoPac® 6, 10, or 15 mg/mL in subjects with prostate cancer scheduled for prostatectomy.
- Trial name
- NCT03077659
- Testing
- NanoPac®
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- NanOlogy, LLC
Metastatic Castration Resistant Prostate Cancer
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination with Other Anticancer Agents in Patients with Metastatic Castration Resistant Prostate Cancer
- Trial name
- RAMP (NCT04179396)
- Testing
- Rucaparib, Enzalutamide, Abiraterone
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- pharmaand GmbH
Metastatic Castration-Resistant Prostate Cancer
Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer
The study will evaluate how safe and effective abemaciclib is when given to participants whose metastatic prostate cancer progresses after they had received several previous treatments.
- Trial name
- CYCLONE 1 (NCT04408924)
- Testing
- Abemaciclib
- Where
- 14 sites in United States, France and 1 more
- Volunteers
- 44 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
This phase II trial studies how well hydroxychloroquine works in treating patients with previously treated prostate cancer. Autophagy destroys proteins and other substances in cells and may be used by prostate cancer cells to…
- Trial name
- NCT00726596
- Testing
- hydroxychloroquine
- Where
- 5 sites in United States
- Volunteers
- 64 people
- Sponsor
- Rutgers, The State University of New Jersey
Intermediate Risk Prostate Cancer, Castration-resistant Prostate Cancer
VAccination in Early and ADvanced Prostate caNCEr
This is a clinical trial of a new treatment for prostate cancer that is a type of vaccine that could be a new way to treat cancer.
- Trial name
- ADVANCE (NCT03815942)
- Testing
- ChAdOx1-MVA 5T4 vaccine, Nivolumab Infusion [Opdivo]
- Where
- 2 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- University of Oxford
Prostate Cancer
LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
This is a Phase Ib/II open label clinical trial in patients with metastatic castration resistant prostate cancer. The objective of the phase Ib portion of the study is to establish the maximum tolerated dose (MTD) and dose…
- Trial name
- NCT02494921
- Testing
- Docetaxel-PNP, Ribociclib, Prednisone
- Where
- 6 sites in United States
- Volunteers
- 43 people
- Sponsor
- Rahul Aggarwal